logo_new.jpg
ObsEva SA to Participate in Upcoming Investor Conferences
February 22, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
January 23, 2019 03:28 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
January 23, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
January 02, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
December 21, 2018 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...
logo_new.jpg
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
December 07, 2018 12:12 ET | ObsEva SA
       Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
logo_new.jpg
ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018
December 06, 2018 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – December 6, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva SA to Host R&D Investor Day December 7, 2018
November 29, 2018 01:30 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...
logo_new.jpg
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
November 28, 2018 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
logo_new.jpg
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
November 08, 2018 01:15 ET | ObsEva SA
IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg...